Predicting peritoneal metastasis in gastric cancer using radiomics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop an intelligent analysis system that utilizes radiomics to predict the risk of peritoneal metastasis in patients with advanced gastric cancer. By analyzing conventional CT images, the system will extract and combine relevant radiomic features to improve detection and facilitate timely treatment decisions. The study will validate the effectiveness of this approach through observational methods, focusing on patients diagnosed with advanced gastric cancer who meet specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
* (2) with both enhanced CT and laparoscopy;
* (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
* (4) without other evidence of distant metastasis, and no stage IV features on CT.

Exclusion Criteria:

* (1) previous abdominal surgery;
* (2) previous abdominal malignancies or inflammatory diseases;
* (3) time intervals between CT and laparoscopy longer than 2 weeks;
* (4) CT image artifacts that undermine peritoneal lesion assessment.

Where it's running

• Peking University Cancer Hospital & Institute
  Beijing, China Recruiting
• Fujian Medical University Union Hospital
  Fuzhou, China Recruiting
• Affiliated Cancer Hospital and Institute of Guangzhou Medical University
  Guangzhou, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, China Recruiting
• Nanfang Hospital of Southern Medical University
  Guangzhou, China Recruiting
• Sun Yat-Sen University Cancer Hospital
  Guangzhou, China Recruiting

Study contacts

• Study coordinator: Di Dong, Ph.D
• Email: di.dong@ia.ac.cn
• Phone: +86 010-82618465

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.